A comparison of strategies for identifying patients at risk for carbapenem-resistant or extended β-lactam-resistant Pseudomonas aeruginosa.
Walaiporn WangchindaKeith S KayeTwisha S PatelOwen R AlbinLouis SaravolatzJoshua G PetrieJason M PoguePublished in: The Journal of antimicrobial chemotherapy (2024)
Clinicians concerned about CR in P. aeruginosa should consider the likelihood of EBR when making treatment decisions. A simple approach of assessing recent history of CR isolation or carbapenem usage performed similarly to more complex scoring tools and offers a more pragmatic way of identifying patients who require coverage for resistant P. aeruginosa.
Keyphrases
- pseudomonas aeruginosa
- end stage renal disease
- ejection fraction
- newly diagnosed
- chronic kidney disease
- acinetobacter baumannii
- peritoneal dialysis
- prognostic factors
- palliative care
- study protocol
- healthcare
- clinical trial
- biofilm formation
- multidrug resistant
- health insurance
- affordable care act
- smoking cessation
- double blind